Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

1. Tuberculosis

Tuberculosis T T uberculosis uberculosis NICE guideline Published: 13 January 2016 nice.org.uk/guidance/ng33 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Tuberculosis (NG33) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 178Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Preventing TB 5 1.2 Latent TB 15 1.3 Active TB 24 1.4 Drug resistant TB 40 1.5 Infection control 42 1.6 Case finding 47 1.7

2016 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Programmatic management of latent tuberculosis infection in the European Union

Programmatic management of latent tuberculosis infection in the European Union SCIENTIFIC ADVICE Programmatic management of latent tuberculosis infection in the European Union www.ecdc.europa.euECDC SCIENTIFIC ADVICE Programmatic management of latent tuberculosis infection in the European Union ii This guidance was commissioned by ECDC and coordinated by Senia Rosales Klintz, Netta Beer and Marieke J. van der Werf with the support of Helena de Carvalho Gomes (ECDC). The inventory of expert (...) Kingdom), and its members: Judith Bruchfeld (Sweden); Josie Garrett (United Kingdom); Walter Haas (Germany); Einar Heldal (Norway); Rein Houben (United Kingdom); Philip LoBue (USA); Mike Mandelbaum (United Kingdom); Alberto Matteelli (Italy); Giovanni Battista Migliori (Italy); Ivan Solovic (Slovakia); and Martina Vašáková (Czech Republic). Suggested citation: European Centre for Disease Prevention and Control. Programmatic management of latent tuberculosis infection in the European Union. Stockholm

2019 European Centre for Disease Prevention and Control - Public Health Guidance

3. Diagnosis of Tuberculosis in Adults and Children: Official ATS/IDSA/CDC Clinical Practice Guidelines

Diagnosis of Tuberculosis in Adults and Children: Official ATS/IDSA/CDC Clinical Practice Guidelines Clinical Infectious Diseases Diagnosis of TB in Adults and Children • CID 2017:64 (15 January) • e1 Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children David M. Lewinsohn, 1,a Michael K. Leonard, 2,a Philip A. LoBue, 3,a David L. Cohn, 4 Charles L. Daley (...) Health, Nashville, Tennessee, 14 Wisconsin State Laboratory of Hygiene, Madison, and 15 University of Arkansas for Medical Sciences, Little Rock Background. Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (tuber- culosis disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). Tuberculosis disease is a leading cause of infectious disease morbidity and mortality worldwide, yet many questions related to its

2017 American Thoracic Society

4. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis

WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links WHO treatment guidelines for isoniazid-resistant (...) tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis View/ Open Rights View Statistics Altmetrics Share Citation World Health Organization . (‎2018)‎. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description xi, 31 p. Gov't Doc # WHO/CDS/TB/2018.7 ISBN 9789241550079 Collections Language English Metadata Related items

2018 WHO

5. Guidance for national tuberculosis programmes on the management of tuberculosis in children

Guidance for national tuberculosis programmes on the management of tuberculosis in children Guidance for national tuberculosis programmes on the management of tuberculosis in children Second editionGuidance for national tuberculosis programmes on the management of tuberculosis in children Second editionWHO Library Cataloguing-in-Publication Data Guidance for national tuberculosis programmes on the management of tuberculosis in children – 2 nd ed. 1.Tuberculosis – diagnosis. 2.Tuberculosis (...) – therapy. 3.Tuberculosis – prevention and control. 4.Child. 5.Tuberculosis, Multidrug-Resistant. 6.National Health Programs. 7.Guideline. I.World Health Organization ISBN 978 92 4 154874 8 (NLM classification: WF 200) © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41

2014 World Health Organisation Guidelines

6. Approaches to detecting tuberculosis in children and youth

Approaches to detecting tuberculosis in children and youth This practice point provides a framework for initiating investigation in children suspected of having infection with  Mycobacterium tuberculosis  (Mtb). Some areas in Canada have a high burden of tubercular disease, with Indigenous populations being most at risk. Tuberculosis (TB) can present either as an acute or subacute illness and both primary or reactivation infection can cause pulmonary or multisystem disease (...) . Tuberculin skin tests and interferon-γ release assays can be used to support a suspected diagnosis. TB elimination in Canada is possible but requires improving social determinants of health, one of the major factors contributing to the spread of TB in populations at risk. Keywords: Bacille-Calmette-Guérin; Break of contact; Latent tuberculosis infection; Mycobacterium tuberculosis; Tuberculosis  

2019 Canadian Paediatric Society

7. Tuberculosis (TB): care of the child and protection of staff and patients

Tuberculosis (TB): care of the child and protection of staff and patients Tuberculosis (TB): care of the child and protection of staff and patients | Great Ormond Street Hospital Google Tag Manager Navigation Search Search You are here Tuberculosis (TB): care of the child and protection of staff and patients Tuberculosis (TB): care of the child and protection of staff and patients Please note: that the NICE Guidance is in the process of being updated and this is expected to be published (...) in October 2015. Update of Clinical Guideline 117 Tuberculosis- clinical diagnosis, and measures for its prevention and control, incorporating PH37 Tuberculosis - Hard to reach Groups. Topics included Diagnostic procedures, Infectious diseases, Mental health/ behavioural conditions, Public health and, Respiratory. M.TB is usually caused by an organism in the mycobacterium tuberculosis complex, usually mycobacterium tuberculosis (M.TB) or mycobacterium Bovis (M. Bovis). M.TB will now be referred to as TB

2015 Publication 1593

8. Handbook on tuberculosis laboratory diagnostic methods in the European Union

Handbook on tuberculosis laboratory diagnostic methods in the European Union TECHNICAL REPORT www.ecdc.europa.eu Handbook on tuberculosis laboratory diagnostic methods in the European Union Updated 2018ECDC TECHNICAL REPORT Handbook on tuberculosis laboratory diagnostic methods in the European Union Updated 2018 ii This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Csaba Ködmön with support from Marieke J. van der Werf, Francis Drobniewski (...) ’ in 2016 and further revised and renamed ‘Handbook on tuberculosis laboratory diagnostic methods in the European Union – Updated 2018’ with changes to Chapters 6.7 and 10.4 in 2018 as new scientific evidence became available. Suggested citation: European Centre for Disease Prevention and Control. Handbook on tuberculosis laboratory diagnostic methods in the European Union – Updated 2018. Stockholm: ECDC; 2018. Stockholm, August 2018 ISBN 978-92-9498-264-3 doi 10.2900/914169 Catalogue number TQ-03-18

2018 European Centre for Disease Prevention and Control - Technical Guidance

9. Clinical Practice Guidelines on Prevention, Diagnosis and Management of Tuberculosis

Clinical Practice Guidelines on Prevention, Diagnosis and Management of Tuberculosis Academy of Medicine Singapore College of Family Physicians, Singapore Singapore Medical Association Chapter of Infectious Disease Physicians College of Physicians, Singapore Chapter of Respiratory Physicians College of Physicians, Singapore MOH Clinical Practice Guidelines 1/2016 Mar 2016 MINISTRY OF HEALTH SINGAPORE Prevention, Diagnosis and Management of Tuberculosis ISBN 978-981-09-8528-8 Ministry of Health (...) development group. Inside Back CoverA Prevention, Diagnosis and Management of Tuberculosis CLINICAL PRACTICE GUIDELINES MOH Clinical Practice Guidelines 1/2016 B Published by Ministry of Health, Singapore 16 College Road, College of Medicine Building Singapore 169854 Printed by Kwok Printers Pte Ltd Copyright © 2016 by Ministry of Health, Singapore ISBN 978-981-09-8528-8 Available on the MOH website: http://www.moh.gov.sg/cpg These guidelines are not intended to serve as a standard of medical care

2016 Ministry of Health, Singapore

10. Guidelines for the Clinical and Operational Management of Drug-Resistant Tuberculosis

Guidelines for the Clinical and Operational Management of Drug-Resistant Tuberculosis Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis 2013 International Union Against Tuberculosis and Lung DiseaseJosé A. Caminero, editor with contributions from Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis 2013 International Union Against Tuberculosis and Lung Disease Armand Van Deun Ignacio Monedero Hans L. Rieder Einar Heldal Edith Alarcón (...) Cécile Macé Riitta A. Dlodlo Paula I. Fujiwara Chen-Yuan Chiang Anthony D. Harries Arnaud Trébucq Raimond Armengol Christophe Perrin Gilles Cesari Donald A. Enarson This publication was made possible thanks to the support of MISEREOR and the U.S. Centers for Disease Control and Prevention’s Coordinating Of? ce for Global Health and National Center for HIV, Viral Hepatitis, STDs and TB PreventionEditor International Union Against Tuberculosis and Lung Disease (The Union) 68 boulevard St Michel, 75006

2013 International Union Against TB and Lung Disease

11. MVA85A vaccine to enhance BCG for preventing tuberculosis. Full Text available with Trip Pro

MVA85A vaccine to enhance BCG for preventing tuberculosis. Tuberculosis causes more deaths than any other infectious disease globally. Bacillus Calmette-Guérin (BCG) is the only available vaccine, but protection is incomplete and variable. The modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) is a viral vector vaccine produced to prevent tuberculosis.To assess and summarize the effects of the MVA85A vaccine boosting BCG in humans.We searched the Cochrane Infectious Diseases Group (...) Specialized Register; Central Register of Controlled Trials (CENTRAL); MEDLINE (PubMed); Embase (Ovid); and four other databases. We searched the WHO ICTRP and ClinicalTrials.gov. All searches were run up to 10 May 2018.We evaluated randomized controlled trials of MVA85A vaccine given with BCG in people regardless of age or HIV status.Two review authors independently assessed the eligibility and risk of bias of trials, and extracted and analyzed data. The primary outcome was active tuberculosis disease

2019 Cochrane

12. What constitutes an effective and efficient package of services for the prevention, diagnosis, treatment and care of tuberculosis among refugees and migrants in the WHO European Region? Themed issues on migration and health

What constitutes an effective and efficient package of services for the prevention, diagnosis, treatment and care of tuberculosis among refugees and migrants in the WHO European Region? Themed issues on migration and health Sally Hargreaves | Kieran Rustage | Laura B Nellums | Jaynaide Powis | James Milburn Santino Severoni | Masoud Dara | Soorej J Puthoopparambil | Jon S Friedland HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 56 What constitutes an effective and efficient package of services (...) for the prevention, diagnosis, treatment and care of tuberculosis among refugees and migrants in the WHO European Region? Themed issues on migration and health, VIIIThe Health Evidence Network The Health Evidence Network (HEN) is an information service for public health decision-makers in the WHO European Region, in action since 2003 and initiated and coordinated by the WHO Regional Office for Europe under the umbrella of the European Health Information Initiative (a multipartner network coordinating all health

2018 WHO Health Evidence Network

13. Guidelines on the management of latent tuberculosis infection

Guidelines on the management of latent tuberculosis infection Guidelines on the management of latent tuberculosis infection© World Health Organization 2015 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce (...) Data Guidelines on the management of latent tuberculosis infection. 1.Latent Tuberculosis. 2.Immunologic T ests. 3.Mycobacterium Tuberculosis – immunology. 4.Antitubercular Agents. 5.Guideline. I.World Health Organization. ISBN 978 92 4 154890 8 (NLM classification: WF 200)Guidelines on the management of latent tuberculosis infection1 Guidelines on the management of latent tuberculosis infection Contents Acknowledgements 2 Abbreviations 5 Declaration and management of conflict of interest 6

2015 World Health Organisation Guidelines

14. Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/IDSA Clinical Practice Guidelines

Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/IDSA Clinical Practice Guidelines Clinical Infectious Diseases IDSA GUIDELINE Of?cial American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis Payam Nahid, 1 Susan E. Dorman, 2 Narges Alipanah, 1 Pennan M. Barry, 3 Jan L. Brozek, 4 Adithya Cattamanchi, 1 Lelia H. Chaisson, 1 Richard E. Chaisson, 2 Charles L (...) of Public Health, Richmond; 4 McMaster University, Hamilton, Ontario, Canada; 5 National Jewish Health, Denver, Colorado; 6 World Health Organization, Geneva, Switzerland; 7 Tuberculosis Control Section, San Francisco Department of Public Health, California; 8 Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; 9 Harvard Medical School, Boston, Massachusetts; 10 McGill University

2016 American Thoracic Society

15. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. Full Text available with Trip Pro

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. A 9-month regimen of isoniazid can prevent active tuberculosis in persons with latent tuberculosis infection. However, the regimen has been associated with poor adherence rates and with toxic effects.In an open-label trial conducted in nine countries, we randomly assigned adults with latent tuberculosis infection to receive treatment with a 4-month regimen of rifampin or a 9-month regimen of isoniazid (...) for the prevention of confirmed active tuberculosis within 28 months after randomization. Noninferiority and potential superiority were assessed. Secondary outcomes included clinically diagnosed active tuberculosis, adverse events of grades 3 to 5, and completion of the treatment regimen. Outcomes were adjudicated by independent review panels.Among the 3443 patients in the rifampin group, confirmed active tuberculosis developed in 4 and clinically diagnosed active tuberculosis developed in 4 during 7732 person

2018 NEJM Controlled trial quality: predicted high

16. Isoniazid for preventing tuberculosis in HIV-infected children. Full Text available with Trip Pro

Isoniazid for preventing tuberculosis in HIV-infected children. Tuberculosis (TB) is an important cause of illness and death in HIV-positive children living in areas of high TB prevalence. We know that isoniazid prophylaxis prevents TB in HIV-negative children following TB exposure, but there is uncertainty related to its role in TB preventive treatment in HIV-positive children.To summarise the effects of TB preventive treatment versus placebo in HIV-positive children with no known TB contact

2017 Cochrane

17. Treatment of Drug-Susceptible Tuberculosis

Treatment of Drug-Susceptible Tuberculosis Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute

2016 Infectious Diseases Society of America

19. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. (Abstract)

Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. Accurate diagnosis of tuberculosis in people living with HIV is difficult. HIV-positive individuals have higher rates of extrapulmonary tuberculosis and the diagnosis of tuberculosis is often limited to imaging results. Ultrasound is such an imaging test that is widely used as a diagnostic tool (including point-of-care) in people suspected of having (...) abdominal tuberculosis or disseminated tuberculosis with abdominal involvement.To determine the diagnostic accuracy of abdominal ultrasound for detecting abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals.To investigate potential sources of heterogeneity in test accuracy, including clinical setting, ultrasound training level, and type of reference standard.We searched for publications in any language up to 4 April 2019 in the following databases

2019 Cochrane

20. Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region (Abstract)

Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region Real-world epidemiological data on the risk of tuberculosis (TB) in patients with immune-mediated diseases treated with biologics are scarce in TB endemic areas. We investigated the incidence of TB in a population-based setting and stratified the risk of TB among different biological therapies.We collected medical data from a territory-wide

2019 EvidenceUpdates